The Patent at Any Price: The Fight For Market Exclusivity in Psychiatric Medications
Hidden in a small blurb in the “Corporate Watch” section of this week’s Wall Street Journal was a piece on pharmaceutical maker Eli Lilly and its blockbuster antidepressant medication Cymbalta. Lilly’s U.S. market exclusivity for the drug was set to… Continue Reading
